Antibody-drug conjugate · Cytotoxic, directed at CD33 · developed by Wyeth Pharmaceuticals Llc, A Subsidiary Of Pfizer
Gemtuzumab ozogamicin is an antibody-drug conjugate in which an anti-CD33 antibody is linked to the cytotoxic agent N-acetyl gamma calicheamicin. It binds CD33 on tumor cells, is internalized, and releases the calicheamicin derivative, which causes double-strand DNA breaks and cell death. It is used in acute myeloid leukemia.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Dec 19, 2025). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06448013 | Phase 1 | Acute Myeloid Leukemia | Recruiting | KURA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Acute Myeloid Leukemia